The NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) cancer clinical trial is expanding with the opening of a new treatment arm.
The National Comprehensive Cancer Network has published new guidelines on anemia and neutropenia.
The National Cancer Institute approved the following clinical research studies last month.
A comprehensive review by University of North Carolina researchers and colleagues highlights the optimal ways that focused, high-dose radiation can be delivered to various types of tumors while sparing normal tissue and mitigating long-term side effects.
City of Hope is recruiting patients for a phase II clinical trial to investigate whether pills containing white button mushroom extract could regulate the immune system, affecting prostate-specific antigen levels to either remain stable or decline.
FDA has granted accelerated approval to Keytruda (pembrolizumab) in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma.
FDA has accepted the company’s supplemental New Drug Application for Tibsovo (ivosidenib tablets) as a potential treatment for patients with previously treated IDH1-mutated cholangiocarcinoma.
FDA has accepted the supplemental Biologics License Application for Opdivo (nivolumab) for the adjuvant treatment of patients with surgically resected, high-risk muscle-invasive urothelial carcinoma, based on results from the CheckMate -274 trial.
The European Commission has approved an additional indication for the oral once-daily therapy Xtandi (enzalutamide) for adult men with metastatic hormone-sensitive prostate cancer (mHSPC, also known as metastatic castration-sensitive prostate cancer or mCSPC).
The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma.
